Peter Libby MD
Mallinckrodt Professor of Medicine, Harvard Medical School; Cardiovascular Specialist, Brigham and Women’s Hospital, Boston, MassachusettsDr. Peter Libby is a cardiovascular medicine specialist at Brigham and Women’s Hospital in Boston, Massachusetts, and is the Mallinckrodt Professor of Medicine at Harvard Medical School in Boston. From 1998 through 2014, Dr. Libby served as the Chief of Cardiovascular Medicine at Brigham and Women’s Hospital. He holds honorary degrees from Harvard University in Cambridge, Massachusetts, from the University of Lille, France, from Laval University in Québec, and from J.W. Goethe Universität, Frankfurt am Main, Germany.
His areas of clinical expertise include general and preventive cardiology. His current major research focus is the role of inflammation in vascular diseases such as atherosclerosis. Dr. Libby has a particular devotion to translating laboratory studies to pilot and then large-scale clinical cardiovascular outcome trials.
He has published extensively in medical journals, including Circulation and The New England Journal of Medicine, among others. He is also active in many organizations, including the American College of Cardiology and the American Heart Association, and was elected to the American Society for Clinical Investigation, the Association of American Physicians, and the Association of University Cardiologists, where he served as President.
Disclosures
- Consultant: Libby is an unpaid consultant to or is involved in clinical trials for: Amgen; AstraZeneca; Baim Institute; Beren Therapeutics; Esperion Therapeutics; Genentech; Kancera; Kowa Pharmaceuticals; Medimmune; Merck; Norvo Nordisk; Novartis; Pfizer; and Sanofi-Regeneron.
- Advisory boards: Amgen; Caristo Diagnostics; Cartesian Therapeutics; CSL Behring; DalCor Pharmaceuticals; Dewpoint Therapeutics; Elucid Bioimaging; Kancera; Kowa Pharmaceuticals; Olatec Therapeutics; Medimmune; Novartis; PlaqueTec; TenSixteen Bio; Soley Therapeutics; XBiotech
- Board of directors: XBiotech
- Financial interest: Xbiotech; TenSixteen Bio; Soley Therapeutics
- Research funding: Libby receives funding support from: National Heart, Lung, and Blood Institute (1R01HL134892, 1R01HL163099-01, and 1R01HL163099-01); American Heart Association (18CSA34080399); RRM Charitable Fund; Simard Fund. Dr. Libby’s laboratory has received research funding from Novartis.
Dr. Libby’s interests were reviewed and are managed by Brigham and Women’s Hospital and Mass General Brigham in accordance with their conflict-of-interest policies.
Recent Contributions to PracticeUpdate:
- Cholesterol, Inflammation and Immunotherapy: Current Implications and Future Directions
- Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy
- Rationale and Contemporary Options for High Intensity Cholesterol Treatment: PCSK-9 Inhibitors
- A Primer on Lipid Management in Diabetic Patients Without CV Disease
- Dr. Peter Libby on the FOURIER Trial
- Inflammatory and Cholesterol Risk in the FOURIER Trial
- Rationale and Contemporary Options for High-Intensity Cholesterol Treatment: Statins
- ACC 2018: Late-Breakers Recommendations From Dr. Peter Libby
- Coronary Adventitial and Perivascular Adipose Tissue Inflammation in Patients With Vasospastic Angina
- 2017 Top Stories in Cardiology: Novel Therapies Plumb the Depths of Cholesterol and Can Improve Cardiovascular Outcomes